Cary Street Partners Financial LLC Takes Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Cary Street Partners Financial LLC purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 1,079 shares of the company's stock, valued at approximately $358,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. R Squared Ltd acquired a new stake in Medpace during the 4th quarter worth $30,000. SBI Securities Co. Ltd. purchased a new stake in shares of Medpace in the fourth quarter valued at about $31,000. Jones Financial Companies Lllp boosted its stake in shares of Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares during the period. Lindbrook Capital LLC grew its holdings in shares of Medpace by 27.6% during the fourth quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock worth $45,000 after buying an additional 29 shares during the last quarter. Finally, Assetmark Inc. increased its position in Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock valued at $57,000 after acquiring an additional 29 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Analyst Ratings Changes

A number of analysts have weighed in on MEDP shares. William Blair reaffirmed a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. TD Cowen lowered shares of Medpace from a "buy" rating to a "hold" rating and lowered their price objective for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Leerink Partners began coverage on shares of Medpace in a research report on Monday, March 24th. They set a "market perform" rating and a $330.00 price objective for the company. Leerink Partnrs upgraded shares of Medpace to a "hold" rating in a research note on Monday, March 24th. Finally, Robert W. Baird dropped their price target on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 23rd. Eleven research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Medpace currently has a consensus rating of "Hold" and a consensus price target of $349.30.

Insider Buying and Selling at Medpace

In other Medpace news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction on Thursday, April 24th. The stock was sold at an average price of $301.82, for a total transaction of $516,715.84. Following the completion of the transaction, the director now owns 2,998 shares of the company's stock, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 20.30% of the stock is currently owned by insiders.

Medpace Trading Up 6.0%

Shares of NASDAQ:MEDP traded up $17.71 during trading on Monday, hitting $313.74. 321,078 shares of the stock were exchanged, compared to its average volume of 346,665. The company has a market cap of $9.02 billion, a PE ratio of 24.84, a P/E/G ratio of 3.81 and a beta of 1.55. The company has a fifty day moving average price of $306.60 and a two-hundred day moving average price of $328.47. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $459.77.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its earnings results on Monday, April 21st. The company reported $3.67 EPS for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. The company had revenue of $558.57 million for the quarter, compared to the consensus estimate of $528.38 million. Medpace had a return on equity of 51.48% and a net margin of 19.17%. During the same period in the previous year, the business earned $3.20 earnings per share. Equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.